Terms: = Breast cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Clinical Outcome
11 results:
1. Treatment of Metastatic or High-Risk Solid cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract] [Full Text] [Related]
2. The Influence of Single Nucleotide Polymorphisms and Adjuvant Radiotherapy on Systemic Inflammatory Proteins, Chemokines and Cytokines of Patients With breast cancer.
Lewin NL; Luetragoon T; Andersson BÅ; Oliva D; Nilsson M; Strandeus M; Löfgren S; Rutqvist LE; Lewin F
Anticancer Res; 2019 Mar; 39(3):1287-1292. PubMed ID: 30842160
[TBL] [Abstract] [Full Text] [Related]
3. Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study.
Hong CQ; Zhang F; You YJ; Qiu WL; Giuliano AE; Cui XJ; Zhang GJ; Cui YK
BMC Cancer; 2015 Jul; 15():548. PubMed ID: 26209438
[TBL] [Abstract] [Full Text] [Related]
4. Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism.
Voss MJ; Möller MF; Powe DG; Niggemann B; Zänker KS; Entschladen F
BMC Cancer; 2011 May; 11():158. PubMed ID: 21535870
[TBL] [Abstract] [Full Text] [Related]
5. IL-15 and il-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract] [Full Text] [Related]
6. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and il-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
J Transl Med; 2010 Jun; 8():53. PubMed ID: 20529245
[TBL] [Abstract] [Full Text] [Related]
7. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
[TBL] [Abstract] [Full Text] [Related]
8. Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Recchia F; Candeloro G; Necozione S; Accorsi P; Recchia CO; Tombolini V; Rea S
Anticancer Res; 2010 Jan; 30(1):209-15. PubMed ID: 20150637
[TBL] [Abstract] [Full Text] [Related]
9. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
Svane IM; Pedersen AE; Nikolajsen K; Zocca MB
Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968
[TBL] [Abstract] [Full Text] [Related]
10. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.
Nicolini A; Carpi A; Rossi G
Cancer Lett; 2007 Jun; 251(2):330-8. PubMed ID: 17215077
[TBL] [Abstract] [Full Text] [Related]
11. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma.
Arun B; Slack R; Gehan E; Spitzer T; Meehan KR
Cancer; 1999 Jan; 85(1):93-9. PubMed ID: 9921979
[TBL] [Abstract] [Full Text] [Related]
